- Eve & Co (EVE) has closed its C$0.5 million private placement with a multi-national medical cannabis company
- Eve will use the proceeds for working capital and general corporate purposes
- The multi-national will negotiate terms to lease a portion of the cultivation and processing areas in Eve’s Strathroy facility
- Eve & Co holds cultivation and processing licenses under the Cannabis Act (Canada) for the production and sale of cannabis products
- Eve & Co (EVE) is down by 9.52 per cent trading at $0.19 per share
Eve & Co (EVE) has closed its C$0.5 million private placement with a multi-national medical cannabis company.
Eve sold 2,777,778 units priced at $0.18 per unit.
Each unit consists of one common share and one-half of one common share purchase warrant.
Each warrant is exercisable into one common share priced at $0.25 for a period of two years from closing.
The multi-national, being the sole purchaser in the private placement, will negotiate terms to lease a portion of the cultivation and processing areas in Eve’s Strathroy facility.
The company will use the proceeds for working capital and general corporate purposes.
Melinda Rombouts, the CEO and President of Eve & Co remarked,
“We are excited about this partnership, which aligns with Eve’s focus on expanding and growing into foreign markets. We believe this strategic alliance will be a great asset as we continue to focus on achieving the highest-quality product on a large scale with consistency and reliability for the foreign markets.”
Eve & Co holds cultivation and processing licenses under the Cannabis Act (Canada) for the production and sale of cannabis products.
Eve & Co (EVE) is down by 9.52 per cent trading at $0.19 per share as of 9:41 am ET.
